Spurred by recent lawsuits, the FDA is scheduled to hold a two-day hearing this week on whether to allow drugmakers more latitude in promoting therapies off-label.
With about 70 million users in six million health-related groups, drugmakers have tremendous opportunity to reach key audiences on Facebook. Here's how.
Agencies are testing out strategies to reach gender parity at a time when questions of discrimination are still front and center.
The discontinuation of the Take It From a Fish campaign can serve as an example of the common ups-and-downs of pharma marketing.
Using a med-tech strategy may help stem concern about CAR T-cell technology's complicated distribution and anticipated high prices, said Novartis exec.
The move away from a fee-for-service reimbursement model and the arrival of promising new technology have created demand for big data in healthcare.
Anti-DTC measures are unlikely to be enacted even though the backlash itself is a function of political change.
Providing financial assistance to patients has become a common refrain in drugmakers' defense of high-priced drugs.
President Barack Obama's recently unveiled Precision Medicine Initiative hopes to develop a new model of patient-driven research with the promise of accelerating biomedical discoveries and provide clinicians with new tools, knowledge, and therapies.
Sandoz will need to put across the biosimilar concept to doctors as it challenges Neupogen and Teva's Granix
Programmatic ad buying hasn't exactly taken over the industry, but its approach has precipitated a paradigm shift, media experts say.
Merck said in November that a long-running clinical trial finally demonstrated the impact of its Zetia cholesterol-lowering treatment on cardiovascular outcomes.
Hospira is taking to the courts to fight off generic threats to its hospital sedation drug Precedex
Two FDA guidance documents on how health product manufacturers may participate in social media have each drawn criticism from affected industry and consumer groups.
FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic communications environment.
Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.
Months before FDA's expected main venture this summer into regulating medical marketers' activities in social media, the industry reacted sharply to a draft guidance the agency issued in January
Are the Ranbaxy Laboratories and Sun Pharmaceutical recalls of prescription generics isolated incidents, or signs of a pharma culture in which corners are too often cut in the interest of profits and process?
Allowing copies of branded biologic medicines to share the original drug's non-proprietary name will have little or no consequence for patient safety, most stakeholders and experts said during a February workshop convened by FTC
The ethical spotlight is once again pointed at Merck & Co., Inc. In December, Vanity Fair put a human face on the controversy swirling around the company's NuvaRing contraception product.
Last year's merger of two big ad networks prompted indie shops to step up recruiting, and get creative. Blanketed media buys, organ-themed T-shirts and ice cream giveaways are among tactics.
Big pharma marketers who've been complaining to Washington for decades about the unregulated nibbling at their market shares won historic relief when the Drug Quality and Security Act was signed into law on Nov. 27.
Aggressive new recommendations for treating patients at high risk of cardiovascular disease could significantly alter the treatment landscape.
Will J&J ever regain its once stellar reputation for ethics and social responsibility?
According to a Stericycle ExpertRecall report, drug and pharmaceutical recalls reported by FDA in the second quarter of this year surged 127% over the previous quarter
Data-sharing advocates have been calling on manufacturers to release the raw data from clinical trials so that researchers can look at all the parameters related to specific drugs
A study found that removing financial barriers to medication adherence improves the quality of patient care, but does not result in major savings
There's been a paradigm shift among buy-side companies, which have finally accepted the fact that external R&D is going to be a big part of the future.
The White House has released its proposed budget for the 2014 fiscal year, and while it gives a modest boost to Health and Human Services, it also seeks to extract more cost savings from pharmas.
With sequester cuts taking effect at FDA and no sign of a deal to end them in sight, it's certain the approvals process will slow as the agency absorbs the loss.
With the dust beginning to settle on CMS's final rule for the Sunshine provisions of Obamacare, winner and losers are starting to emerge from the fine print
What's been called the first clinical study protocol developed using crowdsourcing methods received the FDA's imprimatur.
Pushing back against complaints that the drug approvals process moves too slowly in the US, FDA issued a report saying it kept pace with its 2011 showing
Due to the trend toward increased healthcare access, healthcare could go from being an additional benefit to "being regarded everywhere as a basic human right." That would mean more drugs prescribed.
Hearing patient activists and pharma and agency execs talk about connecting through social and other online channels brings to mind a room full of awkward wallflowers at a high school dance.
A Bernstein Research report shows that, essentially, "Pipeline success rates across all phases of development have been slowly worsening or at best staying flat, depending on the phase (preclinical through registration)."
The winner of Sanofi's second Data Design Diabetes Innovation Challenge was a community-focused proposition that focuses on face-to-face interactions
Scientists are getting closer to finding the killer app in treating hepatitis C, but it may be too soon to pick a winner.
FDA issues may deter drugmakers from engaging in social media, but that's no excuse to ignore what audiences are saying on these platforms
Community Catalyst has declared war on prescription co-pay cards and coupons, calling the sales tools nothing more than kickbacks and bribes.
Why the Susan G. Komen for the Cure Foundation's previously unassailable brand in healthcare fundraising may have sustained some permanent damage.
News of WebMD's planned sale—since aborted—surprised many observers.
Everyone in biopharma knows that manufacturers are spending more to develop drugs that earn less than they did ten years ago, but a new study has put some eye-popping numbers on the industry's dwindling returns.
A little over half of US girls ages 13 to 17 have not gotten even one dose of the HPV vaccine
After Facebook's decision on August 15 to enforce open walls on the site's pharma pages, companies had two options: close down their pages altogether, or let the public openly comment on their products.
Oral anticoagulant Eliquis (apixaban) has demonstrated superior efficacy and bleeding profile to standard warfarin therapy. Barring any bombshells, that should be enough for this agent, being developed by Pfizer and Bristol-Myers Squibb, to get US approval and form a compelling sales narrative in the warfarin-alternative market, analysts say.
The FDA is moving cautiously on a call by the Institute of Medicine (IOM) to scrap the approvals process for many medical devices.
FDA issued draft guidance on mobile medical apps, focusing narrowly on those programs that augment regulated medical devices or turn mobile devices into medical devices.
Pharmaceutical R&D productivity hasn't always been an oxymoron. What has gone wrong, and how to improve it, was the subject of a Bernstein Research investor conference in May that pulled together eight industry experts from a variety of backgrounds.
The Patient Protection and Affordable Care Act turned one in March, and it was, for the drug industry, an ambivalent occasion.
- BI and Lilly face a new challenge: how to market a diabetes drug to cardiologists
- Mylan CEO defends EpiPen strategy, questions pricing model in the U.S.
- Five things for pharma marketers to know: Wednesday, December 7, 2016
- Matt Brown leaves Guidemark Health after merger falls through
- Five things for pharma marketers to know: Monday, December 5, 2016
- Omnicom merges AgencyRx, Flashpoint and three other agencies to form DDB Health
- No free lunch for docs: Sponsored meals linked to more prescriptions
- Non-profit behind Free Killer Tan wants parents to practice sun safety
- Allergan draws on A-list celebs to drive engagement
- Women in senior industry roles improve connections with patients, execs say